GLAXOSMITHKLINE PHARMACEUTICALS LTD.

GlaxoSmithKline Pharmaceuticals Ltd has announced that its Board of Directors will convene on Monday, August 3, 2026. The primary agenda item for this meeting is to consider, approve, and take on record the Un-audited financial results for the first quarter ended June 30, 2026. This announcement is made in compliance with the Listing Obligations and Disclosure Requirements Regulations, 2015.

GlaxoSmithKline Pharmaceuticals Ltd has announced the closure of its trading window for buying or selling company shares. This closure is effective from Wednesday, July 1, 2026, and will remain in effect until 48 hours after the announcement of the Un-audited Financial Results for the first quarter ended June 30, 2026. The specific date for the Board Meeting to declare these results will be communicated in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent potential insider trading activities.

GlaxoSmithKline Pharmaceuticals Ltd has received a Demand Notice dated June 24, 2026, from the National Pharmaceutical Pricing Authority (NPPA) for an alleged overcharging of ₹3,54,12,025. The demand includes ₹1,22,91,163 for alleged overcharging and ₹2,31,20,862 as interest. The company states this is due to charging prices higher than fixed/notified for scheduled formulations. GSK Pharma asserts there will be no impact on its financial or operational activities and plans to file an appeal against the demand order.

GlaxoSmithKline Pharmaceuticals Ltd has informed shareholders about the dispatch of its Annual Report for the Financial Year ended March 31, 2026. Letters with a weblink to access the report have been sent to shareholders whose email addresses are not registered. The company also reiterated the mandatory requirement for shareholders to update their PAN, KYC, and nomination details with their Depository Participant or RTA to ensure uninterrupted electronic payments, including dividends. A dedicated Senior Citizens Investor Cell has been established by the RTA, Kfintech Technologies Limited, to assist senior shareholders.

GlaxoSmithKline Pharmaceuticals Ltd has submitted its Annual Report for the financial year ended March 31, 2026, as per LODR Regulations. The report outlines the company's strategic focus on strengthening its core portfolio and expanding into specialty areas like adult immunisation, cancer care, and Hepatitis B treatment. GSK aims to provide high-quality preventive and curative medicines and vaccines to millions in India. The report includes financial statements, management discussion, and a 10-year performance summary, highlighting a commitment to innovation and accelerating impact in India's evolving healthcare landscape.

GlaxoSmithKline Pharmaceuticals Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. This report, which is part of the Annual Report, aligns with the 9 principles of the National Guidelines on Responsible Business Conduct (NGRBC) set by the Ministry of Corporate Affairs. It covers environmental, social, and governance (ESG) parameters, detailing disclosures on general aspects, management processes, and principle-wise performance. The report aims to enhance the connection between financial reporting and the management of sustainability impacts within the company's operations.

GlaxoSmithKline Pharmaceuticals Ltd has announced its 101st Annual General Meeting (AGM) to be held on Tuesday, June 30, 2026, at 11:00 a.m. via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The agenda includes the adoption of audited financial statements for the year ended March 31, 2026, declaration of a dividend of ₹57 per share, and the re-appointment of a director. Special business items include considering commission for Independent Directors for a five-year period and ratifying the remuneration for the cost auditor for the financial years ending March 31, 2026, and March 31, 2027. The meeting will be conducted in compliance with MCA circulars permitting virtual AGMs.

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the year ended 31st March 2026, reporting a 2% revenue growth to ₹3790 crores. Profit After Tax (PAT) increased by 10% to ₹1012 crores, with EBITDA margins expanding by 290 bps to 34%. The Board of Directors recommended a final dividend of ₹57 per equity share. The company's performance was driven by pricing measures, investments in innovative therapies, and cost management. Supply chain disruptions impacted topline growth, prompting efforts to enhance supply chain resilience. The Oncology business saw a key milestone with Jemperli's first-line approval for endometrial cancer.

GlaxoSmithKline Pharmaceuticals Ltd's board has recommended a final dividend of ₹57 per equity share for FY26, subject to shareholder approval at the AGM. The AGM is scheduled for June 30, 2026, via video conferencing. The record date for determining dividend entitlement is May 29, 2026, with dividend payment on or after July 1, 2026. The company confirms it is not classified as a Large Corporate based on SEBI criteria. Audited financial results for the quarter and year ended March 31, 2026, were approved.

GlaxoSmithKline Pharmaceuticals Ltd's board has recommended a final dividend of ₹57 per equity share for the year ended March 31, 2026, subject to shareholder approval at the AGM. The company has fixed the AGM date as June 30, 2026, and the record date for dividend entitlement as May 29, 2026. Payment will be made on or after July 1, 2026. The board also approved the audited financial results for the quarter and year ended March 31, 2026.